Tecovirimat
Mechanism :
Tecovirimat inhibits the activity of the orthopoxvirus VP37 protein and blocks its interaction with cellular Rab9 GTPase and TIP47, preventing formation of egress-competent enveloped virions.
Indication :
Contraindications :
No contraindications.
Dosing :
13 to <25 kg:
200 mg twice daily orally for 14 days.
25 to <40 kg:
400 mg twice daily orally for 14 days.
≥40 kg:
600 mg twice daily orally for 14 days.
Adverse Effect :
Headache, tachycardia, abnormal EEG, depression, irritability, cheilosis, facial erythema, increased thirst, nausea, abdominal pain, arthralgia.
Interaction :
Midazolam: Tecovirimat may decrease the serum concentration of Midazolam.
Repaglinide: Tecovirimat may increase the serum concentration of Repaglinide.
Hepatic Dose :
No dosage adjustment is necessary